Interplay between Inflammatory Responses and Lymphatic Vessels

Kihyuk Shin1,2 and Seung-Hyo Lee2*
1Department of Medicine, Pusan National University Hospital, Busan 602-739, 2Graduate School of Medical Science and Engineering, and Biomedical Research Center, and KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 305-701, Korea

Lymphatic vessels are routes for leukocyte migration and fluid drainage. In addition to their passive roles in migration of leukocytes, increasing evidence indicates their active roles in immune regulation. Tissue inflammation rapidly induces lymphatic endothelial cell proliferation and chemokine production, thereby resulting in lymphangiogenesis. Furthermore, lymphatic endothelial cells induce T cell tolerance through various mechanisms. In this review, we focus on the current knowledge on how inflammatory cytokines affect lymphangiogenesis and the roles of lymphatic vessels in modulating immune responses.

Keywords: Lymphangiogenesis, Lymphatic vessels, Inflammation, Immune responses

INTRODUCTION

Lymphatic vessels (LVs) exist in most vascularized organs (1). LVs contribute to fluid homeostasis by absorbing tissue fluid and draining it into the venous circulation (2-4). In addition to fluid homeostasis, LVs are also important for immune surveillance (5). In contrast to blood vessels, lymphatic capillaries are connected by monolayers of lymphatic endothelial cells (LECs) and discontinuous basement membrane; thus, dendritic cells (DCs) can migrate into LVs (6,7). Furthermore, LVs in lymph nodes (LNs) and peripheral tissues are highly plastic; hence, LVs undergo proliferation or remodeling during various pathological conditions such as inflammation (8-11).

Recent studies have revealed that lymphangiogenesis during inflammation influences the extent of inflammation and immune responses by modulating leukocyte migration and inducing T cell tolerance. In this review, we will describe the inflammatory mediators that affect lymphangiogenesis and the tolerogenic roles of LVs during immune responses.

FACTORS AFFECTING LYMPHANGIOGENESIS DURING INFLAMMATION

Several factors regulate lymphangiogenesis (Table I). However, here, we focus only on those factors that have been investigated both in vivo and in vitro. Of them, vascular endothelial growth factors (VEGFs), mainly produced by macrophages are the most well-known and well-studied pro-lymphangiogenic factors. VEGF-C/D and VEGF-A have been reported to induce lymphangiogenesis in various inflammatory models (12-14). Blocking the VEGF receptor tyrosine kinase inhibits proliferation and tube formation of umbilical vein endothelial cells and LECs in vitro. Furthermore, in a transgenic

Received on June 28, 2014. Revised on July 22, 2014. Accepted on July 28, 2014. *Corresponding Author. Seung-Hyo Lee, Cellular Immunology Laboratory, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon, Korea. Tel: 82-42-350-4235; Fax: 82-42-350-4240; E-mail: sl131345@kaist.ac.kr

Abbreviations: LV, lymphatic vessel; LEC, lymphatic endothelial cell; DC, dendritic cell; LN, lymph node; VEGF, vascular endothelial growth factor; LT, lymphotoxin; IL, interleukin; HGF, hepatocyte growth factor; FGF, fibroblast growth factor; IFN, interferon; TGF, transforming growth factor
Table I. Inflammatory mediators which have pro- and anti-lymphangiogenic activity

| Factor | Animal model | Reference |
|--------|--------------|-----------|
| Pro-lymphangiogenic factors | | |
| VEGFs | Overexpression of VEGFs induce lymphangiogenesis in the skin | (12-14) |
| LTs | Ectopic expression of LTs induce lymphangiogenesis in the thyroid | (16, 17) |
| IL-8 | IL-8 promotes lymphatic regeneration in the lymphedema model | (17) |
| IL-17 | IL-17 induces corneal lymphangiogenesis in autoimmune dry eye disease | (23) |
| HGF | HGF promotes lymphatic regeneration in the lymphedema model | (18) |
| FGF-2 | FGF-2 implanted in the mouse cornea stimulates lymphangiogenesis | (20) |
| Anti-lymphangiogenic factors | | |
| IFN-γ | IFN-γ inhibits lymphangiogenesis in LPS induced inflammation | (24) |
| TGF-β | Inhibition of TGF-β accelerates lymphangiogenesis in chronic peritonitis | (26) |

Figure 1. The lymphangiogenic balance between pro-lymphangiogenic factors and anti-lymphangiogenic factors regulates lymphatic vascular homeostasis. Lymphangiogenesis under pathophysiological conditions is associated with increased pro-lymphangiogenic factors and/or decreased anti-lymphangiogenic factors. Moreover, FGF-2 induces lymphangiogenesis via both direct and indirect effects, FGF-2 binds LECs and induces proliferation and migration in vitro (21). Furthermore, recent findings suggest that FGF-2 interacts with VEGF-C to induce additional pro-lymphangiogenic activity (22).

Similarly, IL-17 from type 17 T helper (Th17) cells induces lymphangiogenesis in an autoimmune dry eye disease model. IL-17 directly promotes growth of LVS by inducing increased expression of VEGF-D and proliferation of LECs in vitro. Furthermore, in vivo blockade of IL-17 in a model of Th17 dominant autoimmune ocular disease results in a reduction in corneal lymphangiogenesis (23).

By contrast, some inflammatory cytokines have been reported to show anti-lymphangiogenic activity. Interferon (IFN)-γ, which is mainly produced by Th1 cells, inhibits LV formation in an LPS-induced inflammation model. Notably, resolution of increased LVS is dependent on IFN-γ in this model. Furthermore, IFN-γ production by T cells suppresses lymphatic-specific genes in LECs and causes reduction of LV formation in vitro (24).

In addition, in thioglycollate-induced peritonitis and in a lymphedema model, inhibition of transforming growth factor (TGF)-β promotes LV formation (25). Expression of LEC markers, including LYVE-1 and Prox1, is inhibited by TGF-β but is enhanced by a TGF-β type I receptor inhibitor (26).

Therefore, the balance of pro- and anti-lymphangiogenic factors could determine the nature of LVS in various inflammatory conditions (Fig. 1). LVS are involved in immune responses; thus, these results imply that controlling these factors could be a good tool to control lymphangiogenesis and immune responses.
CROSSTALK BETWEEN IMMUNE CELLS AND LYMPHATIC VESSELS

LVs provide pathways for DCs and lymphocyte migration to LNs, thus facilitating inflammation or possible immune tolerance (7,27). For leukocyte trafficking, adhesion molecules like intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 are induced on LECs. Moreover, various chemokines are produced by LECs during inflammation (28,29). Of them, CCL21, which binds to CC-chemokine receptor 7 (CCR7) expressed on DCs and T cells, is the primary determinant of leukocyte antigen presenting cells (APCs). LECs in LNs constitutively express major histocompatibility complex (MHC)-II molecules. Moreover, they endocytose and cross-present antigens in context with MHC-I molecules. Furthermore, CXCL12 was reported to enhance DC transmigration across LECs to LNs (34). Therefore, although CCL21 has a major role in DC migration during inflammation, the expression of other LEC adhesion molecules and chemokines also contributes to migration (29).

In addition to the ability of LECs to control leukocyte trafficking through adhesion molecules, LECs control immune responses via their functions as professional antigen presenting cells (APCs). LECs in LNs constitutively express major histocompatibility complex (MHC)-II molecules. Moreover, they endocytose and cross-present antigens in context with MHC-I molecules to T cells (35-37). However, LECs do not express co-stimulatory molecules such as CD80, CD86, OX40L, or 4-1BBL, thus fail to induce T cell activation and proliferation (38,39). Although the lack of co-stimulatory molecules on LECs implies immunological tolerance, further study is needed to elucidate the exact roles of LECs in CD4 T cell activation.

Recently, it was reported that LECs affect not only CD4 T cell tolerance but also CD8 T cell tolerance, LECs express peripheral tissue antigens (PTA) that are restricted to specific tissues such as skin, gut, pancreas, and central nervous system (40-44). Furthermore, LECs induce deletion or abortive proliferation of PTA-specific CD8 T cells through a lack of co-stimulation or engagement with inhibitory molecules such as PD-L1 (38,45-48). Other co-stimulatory molecules such as HVEM or CD48 are constitutively expressed; thus, their expression suggests that LECs may have immune regulatory roles in steady state as well as in inflammatory conditions (49).

CONCLUSION

So far, we have discussed inflammation, LV formation, and immune regulation. Different pro- and anti-lymphangiogenic factors are produced by different inflammatory stimuli, and their overall effects determine the extent of lymphangiogenesis. Furthermore, although LECs promote leukocyte migration and enhance immune responses, LECs also attenuate T cell-mediated immune responses by mediating tolerance. LECs attract lymphocytes and DCs through cell adhesion molecules and chemokines. In addition, LECs induce CD8 T cell tolerance through PD-L1 and lack of co-stimulatory molecules. However, mechanisms of CD4 T cell tolerance and roles of other inhibitory molecules on LECs need to be investigated. Finally, controlling lymphangiogenesis could be a novel therapeutic strategy to regulate autoimmunity, enhance tumor immunotherapy, and reduce transplantation rejection.

ACKNOWLEDGEMENTS

This study is supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A121145).

CONFLICTS OF INTEREST

The authors have no financial conflict of interest.

REFERENCES

1. Adams, R. H., and K. Alitalo. 2007. Molecular regulation of angiogenesis and lymphangiogenesis, Nat. Rev. Mol. Cell Biol. 8: 464-478.
2. Oliver, G. 2004. Lymphatic vasculature development, Nat. Rev. Immunol. 4: 35-45.
3. Oliver, G., and K. Alitalo. 2005. The lymphatic vasculature: recent progress and paradigms. Annu. Rev. Cell Dev. Biol. 21: 457-883.
4. Gueri, I. N., and M. Detmar. 2006. New insights into the molecular control of the lymphatic vascular system and its role in disease, J. Invest. Dermatol. 126: 2167-2177.
5. Gueri, I. N., and M. Detmar. 2008. The lymphatic system in health and disease, Lymphat. Res. Biol. 6: 109-122.
6. Schulte-Merker, S., A. Sabine, and T. V. Petrova, 2011, Lymphatic vascular morphogenesis in development, physiology, and disease, J. Cell Biol. 193: 607-618.
7. Pflicke, H., and M. Siew, 2009, Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels, J. Exp. Med. 206: 2925-2935.
8. Alitalo, K., T. Tammiela, and T. V. Petrova, 2005, Lymphangiogenesis in development and human disease, Nature 438: 946-953.
9. He, Y., I. Rajantie, K. Pajusola, M. Jeltsch, T. Holopainen,
S. Yla-Herttuala, T. Harding, K. Jooss, T. Takahashi, and K. Alitalo. 2005, Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels, Cancer Res, 65: 4739-4746.

10. Achen, M. G., and S. A. Stacker. 2006, Tumor lymphangiogenesis and metastatic spread—new players begin to emerge, Int. J. Cancer 119: 1755-1760.

11. Katani, R. P., K. Jung, C. Jung, H. Yang, R. A. Schwendener, J. E. Baik, S. H. Han, K. Alitalo, and G. Y. Koh. 2009, Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution, Blood 113: 5650-5659.

12. Jeltsch, M., A. Kaipainen, V. Joukov, X. Meng, M. Lakso, H. Ruddle. 2010, Lymphotoxin-alpha contributes to lymph node lymphangiogenesis, Proc. Natl. Acad. Sci. U. S. A. 107: 15894-15899.

13. Makinen, T., J. Vilkola, S. Mustjoki, T. Karpanen, B. Littlewood-Evans, A. Stuetz, and M. Detmar. 2008, Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor, Am. J. Pathol. 173: 265-277.

14. Martín-Fontecha, A., S. Sebastiani, U. E. Hopken, M. G. Zambruno, J. A. Nagy, H. F. Dvorak, S. Yla-Herttuala, T. Takahashi, and K. Alitalo. 2001, Isolated lymphatic endothelial cells transduce growth survival and migratory signals via the VEGF-C/D receptor VEGFR-3, EMBO J. 20: 4762-4773.

15. Moin, C., M. Iwata, S. H. Lee, T. Doh, D. M. McDonald, and N. Y. Sun, K. Tritsaris, A. J. Hansen, S. Dissing, and Y. Cao. 2012, Collaborative interplay between PGF-2 and VEGF-C promotes lymphangiogenesis and metastasis, Proc. Natl. Acad. Sci. U. S. A. 109: 15894-15899.

16. Okada, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono, 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

17. Oka, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono. 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

18. Oka, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono. 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

19. Okada, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono. 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

20. Saito, Y., H. Nakagami, R. Morishita, Y. Takami, Y. Kikuchi, H. Ruddle. 2010, Lymphotoxin-alpha contributes to lymph node lymphangiogenesis, Proc. Natl. Acad. Sci. U. S. A. 107: 15894-15899.

21. Chang, L. K., G. Garcia-Cardena, F. Farnebo, M. Fannon, E. J. Chen, C. Butterfield, M. A. Moses, R. C. Mulligan, J. Folkman, and A. Kaipainen. 2004, Dose-dependent response of FGF-2 for lymphangiogenesis, Proc. Natl. Acad. Sci. U. S. A. 101: 11658-11663.

22. Choi, I., Y. S. Lee, H. K. Chung, D. Choi, T. Ecoiffier, H. S. Lee, T. A. Fuchslinger, H. K. Lee, and R. Dana. 2011, A novel pro-lymphangiogenic function for Th17/IL-17, Blood 118: 4630-4634.

23. Chauhan, S. K., J. Y. Jin, S. Goyal, H. S. Lee, T. A. Fuchslinger, H. K. Lee, and R. Dana, 2011, A novel pro-lymphangiogenic function for Th17/IL-17, Blood 118: 4630-4634.

24. Katari, R. P., H. Kim, C. Jung, D. K, Koh, B. I. Koh, M. Kim, S. Gollamudi, Y. K., Kim, S. H. Lee, and G. Y. Koh. 2011, T lymphocytes negatively regulate lymph node lymphangiogenesis, Immunology 134: 96-107.

25. Avraham, T., S. Daluvoy, J. Zampell, A. Yan, Y. S. Haviv, S. G. Rodionov, and B. J. Mehran. 2010, Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair, Am. J. Pathol. 177: 3202-3214.

26. Oka, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono, 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

27. Oka, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono. 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

28. Oka, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono. 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

29. Oka, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono. 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

30. Oka, M., C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kanai, and K. Miyazono. 2008, Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis, Blood 111: 4571-4579.

31. Issa, A., T. X. Le, A. N. Shousharti, J. D. Shields, and M. A. Swartz, 2009, Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype, Cancer Res. 69: 349-357.

32. Issa, A., T. X. Le, A. N. Shousharti, J. D. Shields, and M. A. Swartz, 2009, Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype, Cancer Res. 69: 349-357.

33. Kabashima, K., N. Shiraishi, K. Sugita, T. Mori, A. Onoue, M. Kohayashi, J. Sakabe, R. Yoshiki, H. Tamamura, N. Fujii, K. Inaba, and Y. Tokura. 2007, CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells in a stimulus-dependent manner, Blood 119: 205-215.

34. Kabashima, K., N. Shiraishi, K. Sugita, T. Mori, A. Onoue, M. Kohayashi, J. Sakabe, R. Yoshiki, H. Tamamura, N. Fujii, K. Inaba, and Y. Tokura. 2007, CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells in a stimulus-dependent manner, Blood 119: 205-215.

35. Kabashima, K., N. Shiraishi, K. Sugita, T. Mori, A. Onoue, M. Kohayashi, J. Sakabe, R. Yoshiki, H. Tamamura, N. Fujii, K. Inaba, and Y. Tokura. 2007, CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells in a stimulus-dependent manner, Blood 119: 205-215.
Interplay between Inflammatory Responses and Lymphatic Vessels
Kihyuk Shin and Seung-Hyo Lee

flamed lymphatics. J. Cell Sci. 126: 5259-5270.
35. Amatschek, S., E. Kriehuber, W. Bauer, B. Reininger, P.
Menarini, A. Wolfl, N. Schweifer, C. Haslinger, G. Stingl, and
D. Maurer. 2007. Blood and lymphatic endothelial cell-spe-
cific differentiation programs are stringently controlled by the
tissue environment. Blood 109: 4777-4785.
36. Tripp, C. H., B. Haide, V. Facher, M. Sist, H. Peter, J. Farlas,
R. Gschwentner, L. Sorokin, N. Romani, and P. Stoitzner.
2008. The lymph vessel network in mouse skin visualised
with antibodies against the hyaluron receptor LYVE-1.

Immunobiology. 213: 715-728.
37. Lund, A. W., F. V. Durand, S. Hirose, V. R. Raghavan, C.
Nembrini, S. N. Thomas, A. Issa, S. Hugues, and M. A.
Swartz. 2012. VEGF-C promotes immune tolerance in B16
melanomas and cross-presentation of tumor antigen by lymph
node lymphatics. Cell Rep. 1: 191-199.
38. Tewalt, E. F., J. N. Cohen, C. J. Guidi, H. Qiao, S. P.
Fahl, M. R. Coraway, T. P. Bender, K. S. Tung,
A. T. Vella, A. J. Adler, L. Chen, and V. H. Engelhard. 2012.
Lymphatic endothelial cells induce tolerance via PD-L1 and
lack of costimulation leading to high-level PD-1 expression
on CD8 T cells. Blood 120: 4772-4782.
39. Norder, M., M. G. Gutierrez, S. Zicari, E. Cervi, A. Caruso,
and C. A. Guzman. 2012. Lymph node-derived lymphatic
endothelial cells express functional costimulatory molecules and
impair dendritic cell-induced allogenic T-cell proliferation.
FASEB J. 26: 2835-2846.
40. Lee, J. W., M. Epardaud, J. Sun, J. E. Becker, A. C. Cheng,
A. R. Yonekura, J. K. Heath, and S. J. Turley. 2007.
Peripheral antigen display by lymph node stroma promotes
T cell tolerance to intestinal self. Nat. Immunol. 8: 181-190.
41. Nichols, I., A., Y. Chen, T. A. Colella, C. L. Bennett, B. E.
Claussen, and V. H. Engelhard. 2007. Deletional self-tolerance
to a melanocyte/melanoma antigen derived from tyrosinase is
mediated by a radio-resistant cell in peripheral and mesen-
teric lymph nodes. J. Immunol. 178: 993-1000.
42. Gardner, J. M., J. J. Devoos, R. S. Friedman, D. J. Wong,
Y. X. Tan, X. Zhou, K. P. Johannes, M. A. Su, H. Y. Chang,
M. F. Krummel, and M. S. Anderson. 2008. Deletional toler-
ance mediated by extrathymic Aire-expressing cells. Science
321: 843-847.
43. Cohen, J. N., C. J. Guidi, E. F. Tewalt, H. Qiao, S. J.
Rouhani, A. Ruudell, A. G. Farr, K. S. Tung, and V. H.
Engelhard. 2010. Lymph node-resident lymphatic endothelial
cells mediate peripheral tolerance via Aire-independent direct
antigen presentation. J. Exp. Med. 207: 681-688.
44. Fletcher, A. L., V. Lukacs-Kornek, E. D. Reynoso, S. E.
Pinner, A. Bellerme-Pelletier, M. S. Curry, A. R. Collier, R.
I. Boyd, and S. J. Turley. 2010. Lymph node fibroblastic ret-
cicular cells directly present peripheral tissue antigen under
steady-state and inflammatory conditions. J. Exp. Med. 207:
689-697.
45. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Rauler,
and J. P. Allison. 1992. CD28-mediated signalling co-stim-
ulates marine T cells and prevents induction of anergy in T-cell
clones. Nature 356: 607-609.
46. Hawiger, D., K. Inaba, Y. Dossett, M. Guo, K. Mahnke, M.
Rivara, J. V. Ravetch, R. M. Steinman, and M. C.
Nussenzweig. 2001. Dendritic cells induce peripheral T cell
unresponsiveness under steady state conditions in vivo. J.
Exp. Med. 194: 769-779.
47. Hernandez, J., S. Aung, K. Marquardt, and L. A. Sherman.
2002. Uncoupling of proliferative potential and gain of effec-
tor function by CD8+ T cells responding to self-antigens. J.
Exp. Med. 196: 323-333.
48. Martin-Orozco, N., Y. H. Wang, H. Yagita, and C. Dong.
2006. Cutting Edge: Programmed death (PD) ligand-1/PD-1
interaction is required for CD8+ T cell tolerance to tissue
antigens. J. Immunol. 177: 8291-8295.
49. Liu, X., M. Alexiou, N. Martin-Orozco, Y. Chung, R. I.
Nuriev, L. Ma, Q. Tian, G. Kollias, S. Lu, D. Graf, and C.
Dong. 2009. Cutting edge: A critical role of B and T lympho-
cyte attenuator in peripheral T cell tolerance induction. J.
Immunol. 182: 4516-4520.